武田制药Takeda Pharmaceutical（TAK）2025财年第二季度财报「NYSE」（英文版）（80页）.pdf

1、Takeda Quarterly Financial ReportFor the Quarter Ended September 30,2025Table of ContentsFinancial Highlights .3Selected Financial Results .3Revenue by Region .4Recent Developments .5Pipeline and R&D Activities .5Analysis of results of operations,financial position,and cash flow .10Results of Operat

2、ions .10Financial Position .17Cash Flows .19Forecast and Management Guidance .20Interim Dividend for Fiscal 2025.22Condensed Interim Consolidated Financial Statements .23(1)Condensed Interim Consolidated Statements of Profit or Loss .23(2)Condensed Interim Consolidated Statements of Comprehensive In

3、come .24(3)Condensed Interim Consolidated Statements of Financial Position .25(4)Condensed Interim Consolidated Statements of Changes in Equity .27(5)Condensed Interim Consolidated Statements of Cash Flows .29(6)Other Information .31Supplementary Information .321.Pipeline .33I.Clinical Development A

4、ctivities .33II.Recent Pipeline Progress in stage.41III.Projects removed from pipeline .42IV.Research&Development collaborations/partnering .432.Supplementary Revenue Information .48Revenue by region .48Year to date .48Quarterly .49Product Sales Analysis(vs PY Reported Actual).50Year to date .50Quar

5、terly .52Q2 .52Product Sales Analysis(Reported AER&Core CER Change).54Product Forecast .56Financial Appendix .Financial HighlightsSelected Financial ResultsTakeda uses certain non-IFRS measures to supplement the analysis of results of operations under International Financial Reporting Standards(IFRS

6、).Refer to Financial Appendix for the definition and reconciliations of non-IFRS Measures.Financial ResultsSix-month Period Ended September 30,AER*CER*(JPY millions)20242025JPY Change%Change%ChangeRevenue2,384,0282,219,481(164,547)(6.9)%(3.9)%Operating profit350,576253,561(97,015)(27.7)%(26.0)%Profi